Knowledge graph · Cancer
Indolent B-Cell Non-Hodgkin Lymphoma
hematologic malignancy
- Identifier
- CI-CAN-00005561
- Edges
- 741
- Neighbours
- 17 drugs10 trials
- Drawn
- 27 of 27 neighbours (cap 60); table lists every fetched edge
Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.
Most connectedLung Non-Small Cell Carcinoma 3,149Malignant Colorectal Neoplasm 1,866ABL1 298EGFR 276Imatinib 450Dasatinib 321
Neighbourhood
Radial view
Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.
Edges
Every edge, grouped by relationship
Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.
| Relationship | Neighbour | Direction | Evidence level | Cancer context | Support | Claim | Source | Expand |
|---|---|---|---|---|---|---|---|---|
| Indolent B-Cell Non-Hodgkin Lymphoma approved for …APPROVED_FOR16 of 15 | ||||||||
| ← approved for | Bendamustinesmall_molecule 7 source records aggregated | supports | FDA ORIG | Indolent B-Cell Non-Hodgkin Lymphoma | 7 | Regulatory | openfda | graph → |
| ← approved for | Vorasidenibsmall molecule EMA (EU) · approved · 2025-09-17 · Voranigo as monotherapy is indicated for the treatment of predominantly non‑enhancing Grade 2 astrocytoma or oligodendroglioma with an… | |||||||